Search Results - "Coffee, Erin"

Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models by Corcoran, Ryan B., Cheng, Katherine A., Hata, Aaron N., Faber, Anthony C., Ebi, Hiromichi, Coffee, Erin M., Greninger, Patricia, Brown, Ronald D., Godfrey, Jason T., Cohoon, Travis J., Song, Youngchul, Lifshits, Eugene, Hung, Kenneth E., Shioda, Toshi, Dias-Santagata, Dora, Singh, Anurag, Settleman, Jeffrey, Benes, Cyril H., Mino-Kenudson, Mari, Wong, Kwok-Kin, Engelman, Jeffrey A.

“…KRAS is the most commonly mutated oncogene, yet no effective targeted therapies exist for KRAS mutant cancers. We developed a pooled shRNA-drug screen strategy…”
Get full text

The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer by Roper, Jatin, Richardson, Michael P, Wang, Wei Vivian, Richard, Larissa Georgeon, Chen, Wei, Coffee, Erin M, Sinnamon, Mark J, Lee, Lydia, Chen, Peng-Chieh, Bronson, Roderick T, Martin, Eric S, Hung, Kenneth E

“…To examine the in vitro and in vivo efficacy of the dual PI3K/mTOR inhibitor NVP-BEZ235 in treatment of PIK3CA wild-type colorectal cancer (CRC). PIK3CA mutant…”
Get full text

Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer by Coffee, Erin M, Faber, Anthony C, Roper, Jatin, Sinnamon, Mark J, Goel, Gautam, Keung, Lily, Wang, Wei Vivian, Vecchione, Loredana, de Vriendt, Veerle, Weinstein, Barbara J, Bronson, Roderick T, Tejpar, Sabine, Xavier, Ramnik J, Engelman, Jeffrey A, Martin, Eric S, Hung, Kenneth E

“…BRAF(V600E) mutations are associated with poor clinical prognosis in colorectal cancer (CRC). Although selective BRAF inhibitors are effective for treatment of…”
Get full text

mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1 by Faber, Anthony C, Coffee, Erin M, Costa, Carlotta, Dastur, Anahita, Ebi, Hiromichi, Hata, Aaron N, Yeo, Alan T, Edelman, Elena J, Song, Youngchul, Tam, Ah Ting, Boisvert, Jessica L, Milano, Randy J, Roper, Jatin, Kodack, David P, Jain, Rakesh K, Corcoran, Ryan B, Rivera, Miguel N, Ramaswamy, Sridhar, Hung, Kenneth E, Benes, Cyril H, Engelman, Jeffrey A

“…Colorectal cancers harboring KRAS or BRAF mutations are refractory to current targeted therapies. Using data from a high-throughput drug screen, we have…”
Get more information

Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer by Roper, Jatin, Sinnamon, Mark J, Coffee, Erin M, Belmont, Peter, Keung, Lily, Georgeon-Richard, Larissa, Wang, Wei Vivian, Faber, Anthony C, Yun, Jihye, Yilmaz, Ömer H, Bronson, Roderick T, Martin, Eric S, Tsichlis, Philip N, Hung, Kenneth E

“…Abstract PI3K inhibition in combination with other agents has not been studied in the context of PIK3CA wild-type, KRAS mutant cancer. In a screen of…”
Get full text

Mutations in the promoter region of the aldolase B gene that cause hereditary fructose intolerance by Coffee, Erin M, Tolan, Dean R

“…Hereditary fructose intolerance (HFI) is a potentially fatal inherited metabolic disease caused by a deficiency of aldolase B activity in the liver and kidney…”
Get full text

Development of a Colon Cancer GEMM-Derived Orthotopic Transplant Model for Drug Discovery and Validation by MARTIN, Eric S, BELMONT, Peter J, GOEL, Gautam, XIADONG JI, ZHI XIE, TAO XIE, LAMB, John, WEINRICH, Scott L, VANARSDALE, Todd, BRONSON, Roderick T, XAVIER, Ramnik J, VANDER HEIDEN, Matthew G, SINNAMON, Mark J, KAN, Julie L. C, MAHMOOD, Umar, HUNG, Kenneth E, RICHARD, Larissa Georgeon, JING YUAN, COFFEE, Erin M, ROPER, Jatin, LEE, Lydia, HEIDARI, Pedram, LUNT, Sophia Y

“…Effective therapies for KRAS-mutant colorectal cancer (CRC) are a critical unmet clinical need. Previously, we described genetically engineered mouse models…”
Get full text

Increased prevalence of mutant null alleles that cause hereditary fructose intolerance in the American population by Coffee, Erin M, Yerkes, Laura, Ewen, Elizabeth P, Zee, Tiffany, Tolan, Dean R

“…Mutations in the aldolase B gene (ALDOB) impairing enzyme activity toward fructose-1-phosphate cleavage cause hereditary fructose intolerance (HFI). Diagnosis…”
Get full text

Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer by COFFEE, Erin M, FABER, Anthony C, BRONSON, Roderick T, TEJPAR, Sabine, XAVIER, Ramnik J, ENGELMAN, Jeffrey A, MARTIN, Eric S, HUNG, Kenneth E, ROPER, Jatin, SINNAMON, Mark J, GOEL, Gautam, KEUNG, Lily, WEI VIVIAN WANG, VECCHIONE, Loredana, DE VRIENDT, Veerle, WEINSTEIN, Barbara J

“…Abstract Purpose: BRAFV600E mutations are associated with poor clinical prognosis in colorectal cancer (CRC). Although selective BRAF inhibitors are effective…”
Get full text

647 Concomitant BRAF and PI3K/mTOR Blockade is Required for Effective Treatment of BRAFV600E Colon Cancer by Coffee, Erin M, Roper, Jatin, Sinnamon, Mark J, Belmont, Peter, Keung, Lily, Wang, Wei Vivian, Richard, Larissa Georgeon, Goel, Gautam, Weinstein, Barbara J, Bronson, Roderick T, Xavier, RamnikJ, Martin, Eric S, Hung, Kenneth E

Get full text

Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease by Belmont, Peter J, Budinska, Eva, Jiang, Ping, Sinnamon, Mark J, Coffee, Erin, Roper, Jatin, Xie, Tao, Rejto, Paul A, Derkits, Sahra, Sansom, Owen J, Delorenzi, Mauro, Tejpar, Sabine, Hung, Kenneth E, Martin, Eric S

“…Effective treatment options for advanced colorectal cancer (CRC) are limited, survival rates are poor and this disease continues to be a leading cause of…”
Get full text

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model for Sporadic Colorectal Cancer by Roper, Jatin, Richardson, Michael P, Wang, Wei Vivian, Georgeon Richard, Larissa, Chen, Wei Y, Coffee, Erin M, Lee, Lydia, Chen, Peng-Chieh, Bronson, Roderick T, Martin, Eric S, Hung, Kenneth E

Get full text

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib by Corcoran, Ryan B, Ebi, Hiromichi, Turke, Alexa B, Coffee, Erin M, Nishino, Michiya, Cogdill, Alexandria P, Brown, Ronald D, Della Pelle, Patricia, Dias-Santagata, Dora, Hung, Kenneth E, Flaherty, Keith T, Piris, Adriano, Wargo, Jennifer A, Settleman, Jeffrey, Mino-Kenudson, Mari, Engelman, Jeffrey A

“…BRAF mutations occur in 10-15% of colorectal cancers (CRCs) and confer adverse outcome. While RAF inhibitors such as vemurafenib (PLX4032) have proven…”
Get more information

Abstract 3135: Pre-treatment p-EGFR levels in tumors from a genetically engineered mouse model of BRAFV600E colorectal cancer predict response to combined BRAF/EGFR inhibition by Coffee, Erin M., Corcoran, Ryan B., Engelman, Jeffrey A.

“…Abstract BRAFV600E colorectal cancer (CRC) patients do not exhibit responses to single-agent BRAF inhibition due to activation of EGFR. While combined BRAF and…”
Get full text

Abstract NG04: Clinical acquired resistance to RAF inhibitor combinations in BRAF mutant colorectal cancer through MAPK pathway alterations by Corcoran, Ryan B., Ahronian, Leanne G., Van Allen, Eliezer, Coffee, Erin M., Wagle, Nikhil, Kwak, Eunice L., Faris, Jason E., Iafrate, A. John, Garraway, Levi A., Engelman, Jeffrey A.

“…Abstract BRAFmutations occur in ∼10% of colorectal cancers (CRCs) and confer poor prognosis. While RAF inhibitor monotherapy leads to response rates of ∼60% in…”
Get full text

Combination PI3K/MEK inhibition promotes tumor apoptosis and regression inPIK3CAwild-type,KRASmutant colorectal cancer by Roper, Jatin, Sinnamon, Mark J, Coffee, Erin M, Belmont, Peter, Keung, Lily, Georgeon-Richard, Larissa, Wang, Wei Vivian, Faber, Anthony C, Yun, Jihye, Yilmaz, Ömer H, Bronson, Roderick T, Martin, Eric S, Tsichlis, Philip N, Hung, Kenneth E

“…PI3K inhibition in combination with other agents has not been studied in the context ofPIK3CAwild-type,KRASmutant cancer. In a screen of phospho-kinases, PI3K…”
Get full text

Abstract C263: mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1 by Coffee, Erin M., Faber, Anthony C., Costa, Carlotta, Dastur, Anahita, Ebi, Hiromichi, Hata, Aaron N., Yeo, Alan T., J, Elena, Song, Youngchul, Tam, Ah Ting, Boisvert, Jessica L., Milano, Randy J., Roper, Jatin, Kodack, David P., Jain, Rakesh K., Corcoran, Ryan B., Rivera, Miguel N., Ramaswamy, Sridhar, Hung, Kenneth E., Benes, Cyril H., Engelman, Jeffrey A.

“…Abstract Colorectal cancers (CRCs) harboring KRAS or BRAF mutations are refractory to current targeted therapies. Using data from a high-throughput drug…”
Get full text

Abstract PR09: Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS-mutant cancer models by Corcoran, Ryan B., Cheng, Katherine A., Hata, Aaron N., Faber, Anthony C., Ebi, Hiromichi, Coffee, Erin M., Greninger, Patricia, Brown, Ronald D., Godfrey, Jason T., Cohoon, Travis J., Song, Youngchul, Lifshits, Eugene, Shioda, Toshi, Dias-Santagata, Dora, Singh, Anurag, Settleman, Jeffrey, Benes, Cyril H., Mino-Kenudson, Mari, Wong, Kwok-Kin, Engelman, Jeffrey A.

“…Abstract Although KRAS is the most commonly mutated oncogene in human cancer, KRAS has proven difficult to target pharmacologically, and no effective therapies…”
Get full text

Abstract PR8: Insensitivity to RAF inhibition by vemurafenib in BRAF mutant colorectal cancer by EGFR-mediated reactivation of MAPK signaling by Corcoran, Ryan B., Hung, Kenneth E., Flaherty, Keith T., Piris, Adriano, Wargo, Jennifer A., Settleman, Jeffrey, Mino-Kenudson, Mari, Engelman, Jeffrey A., Ebi, Hiromichi, Turke, Alexa B., Coffee, Erin M., Nishino, Michiya, Cogdill, Alexandria P., Brown, Ronald D., Pelle, Patricia Della, Dias-Santagata, Dora

“…Abstract BRAF mutations occur in 10–15% of colorectal cancers (CRCs) and confer adverse outcome in the metastatic setting. While RAF inhibitors such as…”
Get full text

Abstract LB-350: EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition by vemurafenib by Corcoran, Ryan B., Ebi, Hiromichi, Turke, Alexa B., Coffee, Erin M., Nishino, Michiya, Cogdill, Alexandra P., Brown, Ronald D., Dias-Santagata, Dora, Pelle, Patricia Della, Hung, Kenneth E., Flaherty, Keith T., Piris, Adriano, Wargo, Jennifer A., Settleman, Jeffrey, Mino-Kenudson, Mari, Engelman, Jeffrey A.

“…Abstract Oncogenic BRAF mutations occur in 10-15% of colorectal cancers (CRCs) and confer adverse outcome. While RAF inhibitors such as vemurafenib (PLX4032)…”
Get full text